Td Asset Management Inc Puma Biotechnology, Inc. Transaction History

Td Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 10, 2020	SELL	$9.5 - $11.14 $442,700 - $519,124	-46,600 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$7.01 - $13.24 $18,226 - $34,424	2,600 Added 5.91%	46,600 $486,000
Q1 2020 May 15, 2020	BUY	$6.28 - $14.57 $58,404 - $135,501	9,300 Added 26.8%	44,000 $371,000
Q4 2019 Feb 11, 2020	BUY	$6.5 - $10.73 $74,750 - $123,395	11,500 Added 49.57%	34,700 $304,000
Q3 2019 Nov 07, 2019	SELL	$8.75 - $12.85 $14,000 - $20,560	-1,600 Reduced 6.45%	23,200 $250,000
Q2 2019 Aug 01, 2019	SELL	$12.3 - $35.76 $170,970 - $497,064	-13,900 Reduced 35.92%	24,800 $315,000
Q1 2019 May 08, 2019	BUY	$20.77 - $42.37 $803,799 - $1.64 Million	38,700 New	38,700 $1.5 Million
Q1 2018 May 11, 2018	SELL	$59.7 - $99.25 $1.99 Million - $3.31 Million	-33,362 Closed	0 $0
Q4 2017 Feb 02, 2018	SELL	$93.85 - $132.45 $7.38 Million - $10.4 Million	-78,617 Reduced 70.21%	33,362 $3.3 Million
Q3 2017 Nov 09, 2017	BUY	$72.0 - $119.75 $8.06 Million - $13.4 Million	111,979	111,979 $13.4 Million

110

28.3M

27.9K

3.4K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $143M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.